Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex

Lena H. Nguyen, Steven C. Leiser, Dekun Song, Daniela Brunner, Steven L. Roberds, Michael Wong, Angelique Bordey

Research output: Contribution to journalArticlepeer-review

8 Scopus citations


Tuberous sclerosis complex (TSC) is a monogenic disorder characterized by hyperactivation of the mTOR signaling pathway and developmental brain malformations leading to intractable epilepsy. Although treatment with the recently approved mTOR inhibitor, everolimus, results in clinically relevant seizure suppression in up to 40% of TSC patients, seizures remain uncontrolled in a large number of cases, underscoring the need to identify novel treatment targets. The MEK-ERK signaling pathway has been found to be aberrantly activated in TSC and inhibition of MEK-ERK activity independently of mTOR rescued neuronal dendrite overgrowth in mice modeling TSC neuropathology. Here, we evaluated the efficacy of MEK-ERK inhibition on seizures in two mouse models of TSC. We found that treatment with the MEK inhibitor PD0325901 (mirdametinib) significantly reduced seizure activity in both TSC mouse models. These findings support inhibiting MEK-ERK activity as a potential alternative strategy to treat seizures in TSC.

Original languageEnglish
Article number106890
JournalEpilepsy Research
StatePublished - Mar 2022


  • Epilepsy
  • MAPK
  • MEK inhibitor
  • MEK-ERK signaling
  • Seizures
  • Tuberous sclerosis complex


Dive into the research topics of 'Inhibition of MEK-ERK signaling reduces seizures in two mouse models of tuberous sclerosis complex'. Together they form a unique fingerprint.

Cite this